The Role of Serum Magnesium and Calcium on the Association between Adiponectin Levels and All-Cause Mortality in End-Stage Renal Disease Patients

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Markaki, Anastasia ^a   Kyriazis, John ^b   Stylianou, Kostas ^c   Fragkiadakis, George A ^a   Perakis, Kostas ^c   Margioris, Andrew N ^d   Ganotakis, Emmanuel S ^c   Daphnis, Eugene ^c  

^a TECHNOLOGICAL EDUCATIONAL INSTITUTE OF CRETE   (Greece)

^b General Hospital of Chios   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN; C REACTIVE PROTEIN; CALCIUM; MAGNESIUM;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; CALCIUM BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; REFERENCE VALUE;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; BODY COMPOSITION; CALCIUM; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MAGNESIUM; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84871416681     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052350     Document Type: Article

References (58)

1. Rabin KR, Kamari Y, Avni I, Grossman E, Sharabi Y, (2005) Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 3: 465-471.
2. Chandran M, Phillips SA, Ciaraldi T, Henry RR, (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26: 2442-2450.
3. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB, (2005) Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced (inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 90: 4542-4548.
4. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, et al. (2006) Adiponectin and coronary heart disease. A prospective study and meta-analysis. Circulation 114: 623-629.
5. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737.
6. Wannamethee SG, Whincup PH, Lennon L, Sattar N, (2007) Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 167: 1510-1517.
7. Laughlin GA, Barrett-Connor E, May S, Langenberg C, (2007) Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 165: 164-174.
8. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, et al. (2002) Adiponectin in essential hiypertension. J Nephrol 15: 507-511.
9. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimbürger O, Zhang Z, et al. (2004) Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65: 274-281.
10. Chudek J, Adamczak M, Karkoszka H, Budziński G, Ignacy W, et al. (2003) Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 35: 2186-2189.
11. Becker B, Kronenberg F, Kielstein JT, Budziński G, Ignacy W, et al. (2005) Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. Am Soc Nephrol 16: 1091-1098.
12. Iwashima Y, Horio T, Kumada M, Budziński G, Ignacy W, et al. (2006) Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 98: 1603-1608.
13. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, et al. (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134-141.
14. Ignacy W, Chudek J, Adamczak M, Benedetto FA, Cutrupi S, et al. (2005) Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease- a follow-up study. Nephron 101: c18-c24.
15. Nishimura M, Hashimoto T, Kobayashi H, Yamazaki S, Okino K, et al. (2006) Association of the circulating adiponectin concentration with coronary in-stent restenosis in hemodialysis patients. Nephrol Dial Transplant 21: 1640-1647.
16. Menon V, Li L, Wang X, Greene T, Balakrishnan V, et al. (2006) Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17: 2599-2606.
17. Ohashi N, Koto A, Misaki T, Sakakima M, Sakakima M, et al. (2008) Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med (Tokyo, Japan) 47: 485-491.
18. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, et al. (2006) Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 27: 2300-2309.
19. Kistorp C, Faher I, Galatius S, Gustafsson F, Frystyk J, et al. (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112: 1756-1762.
20. Pills S, Mangge H, Wellnitz B, Seelhorst U, Winkelmann BR, et al. (2006) Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 91: 4277-4286.
21. Park SH, Carrero JJ, Lindholm B, Stenvinkel P, (2009) Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. Clin Nephrol 72: 87-96.
22. Zoccali C, Postorino M, Marino C, Pizzini P, Cutrupi S, et al. (2011) Waist circumference modifies the relationship between the adipose tissue cytokines leptin andadiponectin and all-cause and cardiovascular mortality in haemodialysis patients. J Intern Med 269: 172-181.
23. Kollerits B, Fliser D, Heid IM, Ritz E, (2007) Kronenberg F; MMKD Study Group (2007) Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 71: 1279-1286.
24. Qi L, Rimm E, Liu S, Rifai N, Hu FB, (2005) Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care 28: 1022-1028.
25. Cassidy A, Skidmore P, Rimm EB, Welch A, Fairweather-Tait S, et al. (2009) Plasma adiponectin concentrations are associated with body composition and plant-based dietary factors in female twins. J Nutr 139: 353-358.
26. Takaya J, Yamato F, Higashino H, Kaneko K, (2007) Intracellular magnesium and adipokines in umbilical cord plasma and infant birth size. Pediatr Res 62: 700-703.
27. Guessous I, Bonny O, Paccaud, F Mooser V, Waeber G, et al. (2011) Serum calcium levels are associated with novel cardiometabolic risk factors in the population-based CoLaus study. Plos one 6: e18865.
28. Delfini E, Petramala L, Caliumi C, Cotesta D, De Toma G, et al. (2007) Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56: 30-36.
29. Bollerslev J, Rosen T, Mollerup CL, Nordenström J, Baranowski M, et al. (2009) Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 94: 2255-2261.
30. Massy ZA, Drüeke TB (2012) Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 5[Suppl 1]: i52-i61.
31. Young EW, (2007) Mineral metabolism and mortality in patients with chronic kidney disease. Adv Chronic Kidney Dis 14: 13-21.
32. Hsu CW, Lin JL, Lin-Tan DT, Yen TH, Chen KH, et al. (2010) High-calcium dialysate: a factor associated with inflammation, malnutrition and mortality in non-diabetic maintenance haemodialysis patients. Nephrology (Carlton) 15: 313-320.
33. Resnick LM, (1989) Hypertension and abnormal glucose homeostasis. Possible role of divalent ion metabolism. Am J Med 87: 17S-22S.
34. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT, (2007) Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2: 366-373.
35. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A, (2000) Magnesium. An update on physiological, clinical and analytical aspects. Clin Chim Acta 294: 1-26.
36. Sun G, Vasdev S, Martin GR, Gadag V, Zhang H, (2005) Altered Calcium Homeostasis Is Correlated With Abnormalities of Fasting Serum Glucose, Insulin Resistance, and β-Cell Function in the Newfoundland Population. Diabetes 54: 3336-3369.
37. Ybarra J, Doñate T, Jurado J, Pou JM, (2007) Primary hyperparathyroidism, insulin resistance, and cardiovascular disease: a review. Nurs Clin North Am 42: 79-85.
38. Kadowaki T, Yamauchi T, (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439-451.
39. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, et al. (2004) Adiponectin acts in the brain to decrease body weight. Nat Med 10: 524-529.
40. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86: 3815-3819.
41. Díez JJ, Estrada P, Bajo MA, Fernández-Reyes MJ, Grande C, et al. (2009) High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am J Nephrol 30: 244-252.
42. Lo MM, Salisbury S, Scherer PE, Furth SL, Warady BA, et al. (2011) Serum adiponectin complexes and cardiovascular risk in children with chronic kidney disease. Pediatr Nephrol 26: 2009-2017.
43. Dekker JM, Funahashi T, Nijpels G, Pilz S, Stehouwer CD, et al. (2008) Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 93: 1489-1496.
44. Tzanakis I, Virvidakis K, Tsomi A, Tanaka S, Matsuzawa Y, et al. (2004) Intra- and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res 17: 102-108.
45. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, et al. (2012) Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 35: 31-39.
46. Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y, (2007) Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 20: 237-244.
47. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, et al. (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179-1187.
48. Tetta C, Gallieni M, Panichi V, Brancaccio D, (2002) Vascular calcifications as a footprint of increased calcium load and chronic inflammation in uremic patients: a need for a neutral calcium balance during hemodialysis? Int J Artif Organs 25: 18-26.
49. Shen YY, Charlesworlh JA, Kelly JJ, Loi KW, Peake PW, (2007) Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 22: 171-178.
50. Rizza S, Gigli F, Galli A, Micchelini B, Lauro D, et al. (2010) Adiponectin isoforms in elderly patients with or without coronary artery disease. J Am Geriatr Soc 58: 702-706.
51. Kotani K, Wakai K, Shibata A, Fujita Y, Ogimoto I, et al. (2009) Serum adiponectin multimer complexes and liver cancer risk in a large cohort study in Japan. Asia J Cancer Prev 10Suppl: 87-90.
52. Banga A, Bodies AM, Rasouli N, Ranganathan G, Kern PA, et al. (2008) Calcium is involved in formation of high molecular weight adiponectin. Metab Syndr Relat Disord 6: 103-111.
53. Kyriazis J, Kalogeropoulou K, Bilirakis L, Smirnioudis N, Pikounis V, et al. (2004) Dialysate magnesium level and blood pressure. Kidney Int 66: 1221-1231.
54. Cunningham J, Rodri{dotless}guez M, Messa P, (2012) Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J 5 (suppl1): i39-i52i.
55. (2011) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int:76 (Suppl 113) S50-S99.
56. Bosticardo G, Malberti F, Basile C, Leardini L, Libbuti P, et al. (2012) Optimizing the dialysate calcium concentration in bicarbonate haemodialysis. Nephrol Dial Transplant 27: 2489-2496.
57. Kyriazis J, Glotsos J, Bilirakis L, Smirnioudis N, Tripolitou M, et al. (2002) Dialysate calcium profiling during hemodialysis: use and clinical implications. Kidney Int 61: 276-287.
58. Pischon T, Hotamisligil GS, Rimm EB, (2003) Adiponectin: Stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 49: 650-652.